HY

Hyperion DeFi, Inc.

HYPDHealthcareNASDAQ

Biotechnology

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$813,455
+1318.8% YoY
Net Income
-$45.3M
+9.0% YoY
EBITDA
-$43.8M
+5.3% YoY
Free Cash Flow
-$5.7M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 MACD Negative CrossoverHistogram -0.0061, negative momentum
Jul 14 MACD Negative CrossoverHistogram -0.0037, negative momentum
About Hyperion DeFi, Inc.

Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. With a market capitalization of $41.8M, it sits in micro-cap territory. It operates through two segments: Ophthalmic Technology and Digital Assets.

Where HYPD stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, HYPD finished 15.19% below its 150-day moving average ($3.49) and 31.32% below its 200-day moving average ($4.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HYPD overbought or oversold?

At the July 15, 2026 close, HYPD's RSI(14) was 32.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$41.8M
EPS$-7.63
Beta2.50
52W Change-76.0%
ROE-135.3%
Analysis

The balance sheet looks solid with $7.4M in cash comfortably exceeding the $598K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -135.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

A beta of 2.50 means HYPD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, HYPD has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing HYPD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
HYPD: Hyperion DeFi, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance